Progress in Nonhormonal Male Contraception Advances in Early Clinical Studies
May 11, 2026
Early clinical studies highlighted nonhormonal male contraception candidates YCT-529 and ADAM. YCT-529 showed favorable phase 1a safety, while ADAM reported mild transient effects and durability up to 24 months.